Elevated plasma phenylalanine associated with obesity, type 2 diabetes, and cancer risk.

This systematic review integrates epidemiological and molecular evidence concerning the role of phenylalanine homeostasis in metabolic disorders. The study population encompasses individuals with obesity, type 2 diabetes mellitus, and cancer, though specific sample sizes and settings were not reported. The review synthesizes existing literature rather than presenting new primary data.

The analysis indicates that elevated plasma phenylalanine is a significant risk factor for obesity, type 2 diabetes, and cancer. Mechanistically, phenylalanylation of the insulin receptor beta subunit is reported to inhibit insulin signal transduction. Furthermore, phenylalanine and its catabolites are described as impairing mitochondrial function, inducing oxidative stress and inflammation, which ultimately lead to insulin resistance and hepatic steatosis. Conversely, certain derivatives, such as exercise-induced N-lactoylphenylalanine, may suppress appetite and improve glucose homeostasis.

Safety and tolerability data were not reported in the abstract. The authors note that ensuring the continuity, efficacy, and safety of treatment strategies remains a formidable challenge. Key limitations include the absence of quantitative effect sizes, absolute numbers, or confidence intervals for the reported associations. The evidence is observational and mechanistic, meaning it does not establish causation from the epidemiological data provided.

Clinical practice relevance suggests a gradual transition from traditional strict dietary restriction toward personalized, multimodal interventions. These new strategies include nutrition, pharmacology, and enzyme replacement therapy. Clinicians should interpret these findings as associations and mechanistic pathways rather than definitive causal proof for immediate therapeutic changes.